Indication for treatment with TCZ
| n=93 | |
| Joints | 67 (72.0%) |
| Skin | 25 (26.9%) |
| Lung | 20 (21.5%) |
| Myositis | 2 (2.2%) |
| Heart | 1 (1.1%) |
| Tendinitis | 2 (2.2%) |
| Vasculitis | 1 (1.1%) |
| Coexisting Castelman-like disease | 1 (1.1%) |
| Joints only | 50 (53.8%) |
| Joints and skin | 6 (6.5%) |
| Joints and lung | 7 (7.5%) |
| Joints and myositis | 1 (1.1%) |
| Joints, skin and lung | 3 (3.2%) |
| Skin only | 8 (8.6%) |
| Skin and lung | 4 (4.3%) |
| Skin and heart | 1 (1.1%) |
| Skin and tendovaginitis | 2 (2.2%) |
| Skin, lung and myositis | 1 (2.2%) |
| Lung only | 5 (5.4%) |
| Vasculitis only | 1 (1.1%) |
| Coexisting Castelman-like disease only | 1 (1.1%) |
| NA | 3 (3.2%) |
NA, not available; TCZ, tocilizumab.